Urine CXCL10 Chemokine Monitoring Post-renal Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

241 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-28

Study Completion Date

2022-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study investigators will investigate whether early treatment of allograft rejection, as detected by urine CXCL10-monitoring, improves outcomes in renal allograft recipients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Deep Phenotyping of the Renal Allograft to Prognosticate Clinical Outcomes

NCT06438107

Renal Transplant Rejection

NOT_YET_RECRUITING

Observational Cohort Study Renal Transplantation University Hospitals Leuven

NCT06505200

Kidney Transplant Rejection Kidney Transplantation Kidney Transplant Failure

ACTIVE_NOT_RECRUITING

Prediction of Acute Rejection in Renal Transplant

NCT00205257

Kidney Transplant

COMPLETED

Urine Testing to Detect Kidney Transplant Rejection

NCT00337220

Kidney Transplantation Kidney Disease Kidney Failure, Chronic

COMPLETED

Added Value of 18 FDG Pet-scanner in Diagnosis and Management of Subclinical Rejection in Kidney Transplant Patients

NCT04702022

Kidney Transplant Rejection Kidney Transplant; Complications

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Transplant Rejection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant. Sustained elevated levels will trigger performance of a renal allograft biopsy. Any rejection will be treated. Rejection treatment according to clinical standard-of-care

Group Type EXPERIMENTAL

Rejection treatment according to clinical standard-of-care

Intervention Type DRUG

Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection

Control

Urine CXCL10-chemokine levels will be monitored at specific time points post-transplant, but the values are concealed.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rejection treatment according to clinical standard-of-care

Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All consenting adult (age\>=18) renal allograft recipients

Exclusion Criteria

* Human Leucocyte Antigen (HLA) -identical living donor transplantation
* Primary non-function
* Participation in immunosuppression interventional trials

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No